卡格列净与糖尿病患者代谢相关脂肪性肝病:CANVAS研究新发现
本研究为CANVAS和CANVAS-R两项双盲随机对照试验的事后二次分析,纳入10 131例2型糖尿病且心血管高风险患者,比较卡格列净与安慰剂对肝脏相关结局的影响。卡格列净组主要复合终点(ALT改善>30%或ALT正常化)发生率为35.2%,安慰剂组为26.4%(aOR 1.51;95%CI 1.38-1.64;P<.001)。卡格列净可能有益影响肝纤维化。
要点
- 卡格列净组主要复合终点发生率35.2%,安慰剂组26.4%(aOR 1.51;95%CI 1.38-1.64;P<.001)。
- 卡格列净组体重下降>10%者占12.7%,安慰剂组占4.1%(aOR 3.45;95%CI 2.91-4.10;P<.001)。
- 卡格列净改善了部分无创肝纤维化检测指标(NFS、APRI、FNI)。
核心结论
- 在2型糖尿病患者中,与安慰剂相比,卡格列净治疗改善了肝脏生化指标和代谢,并可能有益影响肝纤维化。
研究设计与样本
- CANVAS和CANVAS-R两项大型双盲随机对照试验的二次事后分析,纳入10 131例2型糖尿病且心血管高风险患者,随机接受卡格列净或安慰剂每日一次,中位随访2.4年。
主要发现
- 主要复合终点(ALT改善>30%或ALT正常化)在卡格列净组发生率为35.2%,安慰剂组为26.4%(aOR 1.51;95%CI 1.38-1.64;P<.001)。
- 体重下降>10%(6年内)在卡格列净组为12.7%,安慰剂组为4.1%(aOR 3.45;95%CI 2.91-4.10;P<.001)。
- 卡格列净改善了部分无创肝纤维化检测指标(NFS、APRI、FNI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM); however, there is still no approved pharmacological treatment. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been suggested to beneficially modify liver-related outcomes in patients with diabetes. OBJECTIVE: We aimed to investigate the effects of the SGLT-2 inhibitor canagliflozin on liver-related outcomes in patients with advanced T2DM and high cardiovascular risk. METHODS: We performed a secondary post hoc analysis of 2 large double-blind randomized controlled trials, CANVAS (NCT01032629) and CANVAS-R (NCT01989754), which included patients with T2DM and high cardiovascular risk who were randomized to receive either canagliflozin or placebo once daily. The primary endpoint was a composite of improvement of alanine aminotransferase (ALT) levels >30% or normalization of ALT levels. Secondary endpoints included change in noninvasive tests of fibrosis and weight reduction of >10%. RESULTS: In total, 10 131 patients were included, with a median follow-up of 2.4 years (mean age 62 years; mean duration of diabetes 13.5 years; 64.2% male). Of those patients, 8967 (88.5%) had MAFLD according to hepatic steatosis index and 2599 (25.7%) exhibited elevated liver biochemistry at baseline. The primary composite endpoint occurred in 35.2% of patients receiving canagliflozin and in 26.4% with placebo (adjusted odds ratio [aOR] 1.51; 95% CI, 1.38-1.64; P < .001). Canagliflozin led to improvements in some noninvasive tests of fibrosis (NFS, APRI, FNI). Significant weight reduction of >10% (within 6 years) was achieved in 12.7% with canagliflozin compared to 4.1% with placebo (aOR 3.45; 95% CI, 2.91-4.10; P < .001). CONCLUSION: In patients with T2DM, treatment with canagliflozin vs placebo resulted in improvements in liver biochemistry and metabolism and might beneficially affect liver fibrosis.
引用
- Borisov AN, Kutz A, Christ ER, et al. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. J Clin Endocrinol Metab. 2023. PMID: 37149821. doi:10.1210/clinem/dgad249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。